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Abstract
The widespread introduction of artemisinin-based combination therapy has contributed to
recent reductions in malaria mortality. Combination therapies have a range of advantages,
including synergism, toxicity reduction, and delaying the onset of resistance acquisition.
Unfortunately, antimalarial combination therapy is limited by the depleting repertoire of
effective drugs with distinct target pathways. To fast-track antimalarial drug discovery, we
have previously employed drug-repositioning to identify the anti-amoebic drug, emetine
dihydrochloride hydrate, as a potential candidate for repositioned use against malaria.
Despite its 1000-fold increase in in vitro antimalarial potency (ED50 47 nM) compared with
its anti-amoebic potency (ED50 26–32 uM), practical use of the compound has been limited
by dose-dependent toxicity (emesis and cardiotoxicity). Identification of a synergistic partner
drug would present an opportunity for dose-reduction, thus increasing the therapeutic win-
dow. The lack of reliable and standardised methodology to enable the in vitro definition of
synergistic potential for antimalarials is a major drawback. Here we use isobologram and
combination-index data generated by CalcuSyn software analyses (Biosoft v2.1) to define
drug interactivity in an objective, automated manner. The method, based on the median
effect principle proposed by Chou and Talalay, was initially validated for antimalarial applica-
tion using the known synergistic combination (atovaquone-proguanil). The combination was
used to further understand the relationship between SYBR Green viability and cytocidal ver-
sus cytostatic effects of drugs at higher levels of inhibition. We report here the use of the
optimised Chou Talalay method to define synergistic antimalarial drug interactivity between
emetine dihydrochloride hydrate and atovaquone. The novel findings present a potential
route to harness the nanomolar antimalarial efficacy of this affordable natural product.
Introduction
The prioritisation of combinatorial regimes over monotherapy in malaria has meant that the
analysis of drug interactions has become an increasingly important part of the drug
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development pipeline [1, 2]. Due to the limited number of chemotherapies available, not least
because the development of two novel compounds is doubly challenging, candidates are usu-
ally combined with existing treatments [3, 4]. This strategy delays resistance acquisition and
thereby prolongs the shelf-life of the valuable cohort of current drugs. The ideal partner drugs
for malaria treatment should have matching pharmacokinetics, synergise against drug-resis-
tant strains, be free of significant side-effects, be relatively inexpensive and have no other anti-
microbial activity [4, 5]. The values of combination therapy, namely: (i) better therapeutic
efficacy, (ii) the potential to impede or delay the onset of resistance, (iii) dose reduction, whilst
maintaining potency, and avoiding adverse effects, and (iv) the potential for selective syner-
gism or toxic antagonism, were realised much sooner for diseases like cancer, AIDS and tuber-
culosis [6–8]. Thus, it follows that the methods used to analyse drug interactions have been
evaluated extensively and owe their origins to these disciplines. However, the lack of a stan-
dardised definition for synergy has resulted in confusion and conflict in the field, leading to
many unsubstantiated claims of synergistic potential [8, 9].
We recently reported the findings of a repositioning screen on selected leads from FDA-
approved compound libraries, which identified the anti-amoebic drug emetine dihydrochloride
to have potent antimalarial efficacy [10]. SYBR Green fluorescence flow-cytometric analysis of
K1 P. falciparum isolates showed ED50 values of 47 nM (44.9–49.2) for emetine dihydrochloride
[10]. The natural product anti-protozoal drug (derived from the root of Carapichea ipecacua-
nha), was widely used in the treatment of hepatic and intestinal amoebiasis until it was replaced
in the 1980s by the safer drug, metronidazole. The restriction of its medicinal use was due to
side effects of nausea and vomiting following oral administration and dose-dependent cardio-
toxicity at the higher doses required for use as a tissue amoebicide [11, 12]. The comparative in
vitro ED50 data for Entamoeba species is reported at 26–32 uM [13] as opposed to 47 nM for the
multidrug-resistant K1 [10] and 1 nM for the drug-sensitive 3D7 P. falciparum parasite lines
[10, 13, 14]. Clearly, the dose-dependent toxicity profile for the repositioned use of emetine in
malaria is likely to be varied and therefore merits further investigation. Defining combinatorial
partner drugs with synergistic potential could improve the dose-dependent toxicity profile of
this potent lead by widening therapeutic indices.
Indeed, synergy can occur as a result of the drugs interacting physically or most often as a
consequence of each drug interacting at a molecular level with (same or different) components
of the target [1, 15]. In attempting to identify the desirable occurrence of synergy, researchers
have realised that the definition of additivity is most important. Synergism and antagonism
are referred to as a ‘more than expected’ or ‘less than expected’ additive effect, respectively [9].
The majority of interaction methods are based on two definitions of additivity, namely, Bliss
independence and Loewe additivity. Bliss independence (fractional product method) assumes
that each drug acts independently. Therefore if two drugs A and B, each inhibit at 60%, addi-
tivity = 1- [(1-A)(1-B)], in this case 1-[(1–0.6)(1–0.6)] = 0.84. Thus to be additive, A + B would
be expected to achieve 84% inhibition and deviation above or below this would be considered
as synergistic or antagonistic respectively. Loewe additivity on the other hand, dictates that a
drug cannot interact with itself. Therefore if in fact A and B were the same drug, the interac-
tion can only be additive so 0.5A and 0.5B should be expected to achieve the same effect as
drug 1A or 1B [16, 17]. Drug combinations are therefore additive if inhibition is constant
along a line of equal effective dose. Hence the approach uses a line of constant inhibition (iso-
bole) to define additivity. Deviations above the line (convex) are antagonistic and deviations
below the line (concave) synergistic. Most commonly, the malaria community have classified
drug interactions using the Fractional Inhibitory Concentration (FIC) data based on two out-
puts; the isobologram and sum of the FIC (∑FIC) value where<1 is synergism, equal to 1 is
additivity, >1 is antagonism. However, the lack of standardised definitions between different
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research groups, particularly with regards to ∑FIC cut-offs for classifying an interaction as syn-
ergistic, additive or antagonist has meant that inconsistent, often biased, findings have
appeared throughout the literature [5, 7, 18, 19]. The problem is further potentiated by the var-
iation in treatment regimens used, such as fixed-ratio and checkerboard dosing, which means
that irrelevant comparisons are often drawn between different ratios and dose levels (2, 9, 15–
17). This is not unique to malaria drug combination studies and has in fact plagued the field of
drug combinatory analysis. The lack of consensus prompted efforts by Chou and Talalay to
resolve the issue [6, 9]. Arguing that synergy is a physiochemical rather than statistical issue,
the Chou-Talalay method employs the mass-action law principle to derive a median-effect
equation, (a unified theory derived from four existing physiochemical equations namely; Hen-
derson-Hasselbalch (pH ionization), Hill (higher order ligand binding saturation), Michaelis-
Menten (enzyme kinetics), and Scatchard (receptor binding)). The resulting combination
index (CI) enables the quantitative definition of additivity (CI = 1), with<1 or>1 assigned as
synergism and antagonism respectively. To eliminate subjectivity and permit automated data
analysis, the complex algorithms for median-effect analysis were incorporated into a series of
software programmes (CalcuSyn, CompuSyn), and are now widely used in biomedical science
[6, 8, 17]. The entire shape of the growth inhibition curve is taken into account and the effects
of the drug combination are quantified to see if they have greater effects together than expected
from a simple summation of their individual effects [6]. Applying an automated, non-subjec-
tive method to malaria drug interaction studies would help standardise interaction classifica-
tions and permit more reliable comparisons between research groups.
In order to evaluate the method for antimalarial combinations, our preliminary work
defined interactivity in a drug combination (atovaquone-proguanil) known to be synergistic
against the malarial parasite [20, 21]. Dose-response curves and interaction assays were carried
out in in-vitro cultures of the multidrug resistant K1 Plasmodium falciparum parasite line. The
methodology was subsequently applied to investigate combinatorial regimes for the potent
antimalarial candidate emetine dihydrochloride hydrate with a view to improving its toxicity
profile. The work also introduces and validates use of the CalcuSyn software based on the
Chou-Talalay method for the definition of antimalarial drug interactivity.
Materials and methods
Culture of Plasmodium falciparum
Erythrocytic stage, strain K1, P. falciparum parasites (gifted by Prof John Hyde, University of
Manchester, UK, original source: Thai-K1 clone) were cultured in RPMI 1640 1x (+) L-Gluta-
mine (+) 25 mM Hepes (Gibco, Life Technologies, UK) supplemented with 5% (w/v) lipid rich
bovine serum albumin (Albumax II, Gibco, Life Technologies, New Zealand), 5 ng/ml hypo-
xanthine (Sigma, UK), 0.2% (w/v) glucose (Dextrose Anhydrous, Fisher Scientific, UK) and
50ng/ml gentamycin (Sigma, UK) at 37˚C, under a 5% CO2 5% O2 and 90% N2 gas mixture
(BOC Limited, UK) in accordance with Read and Hyde, 1993 [22]. The parasites were rou-
tinely maintained in O+ human blood (NHS Blood Bank, Manchester, UK). All additives were
sterile filtered at 0.22μm porosity and the complete medium was stored for no more than 2
weeks at 2–8˚C. Continuous cultures were maintained at 5% haematocrit. Sorbitol was used to
maintain synchronicity of the culture. Briefly, pelleted parasites (3,400 rpm for 5mins) were
re-suspended 1:10 in sterile filtered 5% sorbitol ((w/v) in distilled water) and incubated at
room temperature for 5 mins. Prior to continuation of the culture at 5% haematocrit, synchro-
nised parasites were washed 3 x with complete media (3,400 rpm for 5mins). For experimental
set up in a 96-well-plate format final well volumes were 200 μl at 2.5% haematocrit unless
stated otherwise.
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Drug preparation
All compounds were obtained from Sigma Aldrich, UK. Primary stock solutions were prepared
in accordance with manufacturer instructions. In brief, atovaquone (MW = 366.84) was dis-
solved at 5 mg/ml (13.63 nM) in DMSO. For dihydroartemisinin (MW = 284.35) 1.4 mg of the
powder stock was dissolved in 1 ml of DMSO to obtain a primary stock concentration of 5 mM.
Proguanil was dissolved at 1 mg/ml in acetonitrile: water (60/40). All primary stock solutions
were passed through a 0.22 μm porosity filter, aliquoted and stored at -20˚C until further use.
Chloroquine (MW = 515.86) was prepared freshly on the day of use. An initial stock solution
was prepared at 5mM (10.32 mg/ 4 ml) and sterile filtered. For experimental set up the primary
stock solutions were further diluted with complete medium to give final test concentrations.
Drug dosing for ED50 determination
Following preliminary screens (data not shown), refined dose ranges were selected for chloro-
quine (100–350 nM), atovaquone (0.64–40.89 nM), and proguanil (3.77–241.22 μM) to permit
accurate ED50 calculation against the P. falciparum strain K1. Trophozoite stage parasites (0.5–
1%) were treated for 48 hours and parasitaemia was determined using the SYBR Green flow
cytometer method.
SYBR Green staining of erythrocytic stage P. falciparum for flow
cytometry
Following the drug treatment period in a 96 well plate format, an aliquot of each sample
(100 μl) was transferred to a micro-centrifuge tube and washed once with 1 ml 1xPBS (centri-
fugation: 90 seconds at 14, 000 rpm). Each pellet was re-suspended in 1 ml 5 x SYBR Green 1
solution (in 1xPBS) and incubated in the dark at room temperature. After 20 minutes, the
staining solution was removed (90 seconds centrifugation at 14,000 rpm) and the pelleted sam-
ples were re-suspended in 250 μl of the fixation solution (0.37% formaldehyde in 1xPBS, form-
aldehyde solution for molecular biology 36.5%, Sigma, UK) and incubated at 4˚C for 10–15
minutes. Subsequently the samples were washed 3 x in 1xPBS and finally suspended in 1 ml of
1xPBS. Flow cytometric analysis was based on SYBR green fluorescence determined by the
FITC channel (Blue laser, excitation laser line 488 nm EXmax 494 nm/Emmax520 nM) and cell
size (forward scatter, FSC-A) using the BD FACsVerse flow cytometer. Fifty thousand events
were recorded and there were three replicas of each sample. Fluorescent events in drug treated
samples were compared with infected and uninfected blood counterparts and gated accord-
ingly to obtain the percentage parasitaemia.
Derivation of dose-response curves and ED50 values
For each replicate, percentage parasitaemia of drug treated samples was calculated relative to
the infected controls, which were adjusted to equate to 100% growth. GraphPad Prism 5.0 was
used to normalise the data so that the largest value in the data set corresponded to 100% and
the smallest value corresponded 0%. Log-transformed drug concentrations were then plotted
against the dose-response and the ED50 values were determined using nonlinear regression log
(inhibitor) vs. Normalised response-Variable slope (GraphPad Prism 5.0).
Comparison of CalcuSyn-based and FIC analysis of the
dihydroartemisinin-emetine combination
After determination of the ED50, a dose range of 0.125–8 x the ED50 was established by a two-
fold serial dilution. For dihydroartemisinin the doses ranged from 6.3nM to 40nM. For
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emetine the doses ranged was from 63 nM to 400 nM. Co-administration of the compounds
occurred at each level, for example ED50 of dihydoartemisinin was combined with the ED50 of
emetine and 2 x ED50 DHA was combined with 2 x ED50 Eme and so forth. Parasites were
treated at trophozoite stage and incubated for 48h in a 96 well plate format. The SYBR Green
flow cytometer was used to determine drug susceptibility. Triplicate data was converted to an
averaged percentage and analysed for the median-effect using CalcuSyn software (Biosoft).
CalcuSyn interaction assay for malaria
Drug interactions were determined using the isobologram and combination index method
derived from the median-effect principle of Chou and Talalay (CalcuSyn software, Biosoft:
Chou, 2010). The mathematic model, established to assess drug-drug interactions, employs the
median effect principle formula fa/fu = [D/Dm]
m where fa is the fraction of cells affected, fu =
1-fa, the fraction unaffected, D equals the concentration of the drug, Dm the drug dose required
for 50% inhibition, and m the slope of the median effect curve. The isobologram which pro-
vides a graphical representation of the pharmacological interaction is generated by a straight
line connecting the Fa points against the fixed ratio combinations of Drug 1 and Drug 2 on the
x and y axes.
The combination index (CI) is a quantitative representation of the pharmacological interac-
tivity which takes into account both the potency (Dm, ED50) and the shape of the dose
response curve. CI for the classic isobologram (CI = 1) is derived from the formula CI = (D)1/
(Dx)1 + (D)2(Dx)2 + (D)1(D)2/(Dx)1(Dx)2 where (DX)1 and (DX)2 are the concentrations for
Drug 1 and Drug 2 resulting in X% inhibition when acting singly and (D)1 and (D)2 the con-
centrations of the respective drugs when acting in combination to achieve the same (iso-effec-
tive) percentage inhibition [23]. The CI was generated by the CalcuSyn software over a range
of fa levels at different growth inhibition percentages. A CI was interpreted in accordance with
Table 1.
SumFIC calculation and manual isobologram preparation
Combinatory data for the DHA-Eme interactions was analysed using the fraction inhibitory
concentration method as described previously [10]. Briefly, the FIC values were calculated
Table 1. Combinatory index values, recommended symbols and descriptions for classifying syner-
gism or antagonism using the Chou-Talalay method.
Range of CI Symbol Description
<0.1 +++++ Very strong synergism
0.1–0.3 ++++ Strong synergism
0.3–0.7 +++ Synergism
0.7–0.85 ++ Moderate synergism
0.85–0.90 + Slight synergism
0.90–1.10 ± Nearly additive
1.10–1.20 – Slight antagonism
1.20–1.45 –– Moderate antagonism
1.45–3.3 ––– Antagonism
3.3–10 –––– Strong antagonism
>10 ––––– Very strong antagonism
The more broadly defined criteria suggest that the combination index, CI < 1, = 1, and > 1 indicate
synergism, additive effect and antagonism, respectively (Source: CalcuSyn manual, Biosoft, 2006).
doi:10.1371/journal.pone.0173303.t001
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based on ED50, ED75 and ED90 values of the drugs alone and in combination at a constant-
ratio of 1:1 (FIC = Fraction of drug concentration required to produce IC50 when used in com-
bination /Fraction of drug concentration required to produce IC50 when used alone). The Iso-
bologram was generated by plotting the FIC values for one drug against the other. SumFIC
(∑FIC) data were determined by adding the FIC for each drug together at each level of inhibi-
tion (∑FIC = (IC50 of A in mixture/ IC50 of A alone) + (IC50 of B in mixture/ IC50 of B alone)).
∑FIC criteria are highly varied in the literature. Applying the most stringent criteria, a ∑FIC of
1 was interpreted as additive, >1 as antagonism and <1 as synergy [24].
Validation of the CalcuSyn assay for malaria
In order to validate the CalcuSyn method as a useful tool for analysing drug interactions
against the malaria parasite, the known synergistic drug combination, atovaquone and progua-
nil, was used. The initial experiment adopted the treatment regime outlined above and the
doses selected were based on the respective ED50 values obtained previously for atovaquone
(0.24 nM-15.27 nM) and proguanil (1.98 μM-126.81 μM). Triplicate samples were analysed by
SG-FCM after 48 h.
Due to the lack of a synergistic interaction predicted by the initial data the following optimi-
zation steps were trialled: firstly, the activity of the drug stocks was checked (data not shown).
Secondly, the experiment was repeated with an increased atovaquone dose series to account
for a slight shift in the ED50 (0.48 nM-30.53 nM). Thirdly, the treatment duration was adjusted
from 48h to 72h and initiated against ring stage rather than trophozoite stage parasites. This
experiment was simplified by selecting only three dose points (low, mid and high) for each
compound: namely 2.18, 4.36 and 8.72 nM for atovaquone and 7.93, 15.85 and 31.70 μM for
proguanil. The final experiment employed an 8-point dose series, incorporated the optimised
parameters, (initiation at ring stage and 72h incubation) and reduced the atovaquone dose was
(0.27 nM-17.01 nM) to account for the higher potency identified with the longer treatment
period. Drug-susceptibility in all of the optimisation experiments was analysed using the SYBR
Green-based Flow Cytometer Method (SG-FCM) method.
Recovery of parasites treated with the atovaquone-proguanil
combination
Since the dose response curves have failed to achieve > 90% inhibition, and different drugs
and combinations plateau at different levels of inhibition, the atovaquone-proguanil combina-
tion was used to evaluate the accuracy of the SYBR Green FCM method at determining para-
site viability after 72 hours of incubation. In brief, three dose points were selected for each
compound that were previously shown to equate to ED25, ED50 and ED75 levels of inhibition
for a 72h treatment period (0.05, 0.2 and 0.8ng/ml for atovaquone and 2.4, 4.6 and 9.2 μg/ml
for proguanil). Compounds were combined at all doses (ATQ + PG combinations) and
administered singly as controls. Untreated and 3.75% acetonitrile: water (60:40) (proguanil
solvent) controls were also included in the experiment. All treatments were set up in triplicate.
The plate was incubated under conditions described previously and analysed at 72h using the
SG-FCM method. Following the 72h treatment period, the drug/drug combinations were
removed and a limiting serial dilution was performed for each sample (in triplicate). In brief,
50 μl samples of each treatment were transferred to microcentrifuge tubes and washed 3 x in 1
ml of complete media. The pellet was re-suspended in 100 μl of complete media so that the
haematocrit was adjusted from 2.5% to 1.25%. Four 96 well plates were prepared by adding
200 μl of 1.25% haematocrit to each well. Seven 10-fold limiting serial dilutions were per-
formed by adding 20 μl of each sample to row A, mixing thoroughly and transferring 20 μl to
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row B and so forth until row H where the excess 20 μl was discarded. On day seven 100 μl of
spent media was removed from each well and replaced with fresh media and blood at 1% hae-
matocrit, adjusting the final haematocrit to 1.75%. The plates were incubated for a further 10
days and analysed for growth using SG-FCM. In accordance with Sanz et al. (2011) the num-
ber of viable parasites was back-calculated from the day 20 data in a presence/absence manner
using the formula Xn-1 where n was the number of wells able to render growth (determined by
SG-FCM) and was X the dilution factor [25]. The day 20 data was plotted for comparison with
the 72 hour data for both the non-constant and constant ratio combinations.
CalcuSyn analysis of emetine with chloroquine, dihydroartemisinin and
atovaquone
Following validation of the Chou-Talalay method using the atovaquone-proguanil combina-
tion, the interaction between emetine and dihydroartemisinin was reanalysed using the opti-
mised treatment regime. Subsequently the combinations between chloroquine-emetine and
atovaquone-emetine were also analysed using the software. The doses used for each compound
were based on previously determined ED50 values where the respective ED50 concentration
served as the midpoint for a two-fold, constant-ratio dose series (Row E, Table 2).
Results
Determination of dose-response curves and ED50 values
Initially dose-response curves were generated using the SYBR Green flow cytometer (SG-FC)
method to permit accurate ED50 determination of all compounds used in the current study.
Dose-response curves for dihydroartemisinin and emetine dihydrochloride hydrate have been
presented previously with ED50 values of 2.6 nM (2.3–3.17) and 47 nM (44.9–49.2) respectively
[10]. The ED50 values of chloroquine, atovaquone and proguanil presented here (Fig 1) were con-
sistent with those reported elsewhere for the multidrug resistant, P. falciparum, strain K1 [24, 26].
Comparison of CalcuSyn-based and FIC analysis of the
dihydroartemisinin-emetine combination
The results show that similar interactivity classifications were obtained using a constant-ratio
combination of dihydroartemisinin-emetine (1:10 dose ratio based on ED50: ED50 also consid-
ered 1:1 in some studies) when analysed using manual isobologram preparation and ∑FIC
Table 2. The dose series used for the combination of existing antimalarials (AM) with emetine (Eme).
Dose Dose (nM)
Level Dihydroartemisinin Chloroquine Atovaquone Emetine
A 0 0 0 0
B 0.625 28.75 0.136 6.25
C 1.25 57.5 0.272 12.5
D 2.5 115 0.544 25
E 5 230 1.088 50
F 10 460 2.175 100
G 20 920 4.35 200
H 40 1840 8.7 400
AM:Eme ratio 1:10 4.6:1 1:46 —
The constant-ratio for each combination between the existing antimalarial (AM) and Emetine dihydrochloride hydrate (Eme) is also shown.
doi:10.1371/journal.pone.0173303.t002
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calculation Vs. automated CalcuSyn-based analysis. The interactivity determinants for the
CalcuSyn analysis, the combinatory index (CI, equivalent to ∑FIC) and the isobologram plot,
are based on both drug potency and shape of the dose-effect curve. In addition, the output
includes a dose-effect curve and a median-effect plot to provide a figurative depiction of com-
pound potency and conformity to the mass action law, respectively (Fig 2A and 2B). When the
isobolograms and either ∑FIC or CI data were considered, both analyses indicated a predomi-
nantly antagonistic interaction between dihydroartemisinin and emetine across the inhibitory
Fig 1. Dose-response curves and ED50 values for a. chloroquine (CQ), b. atovaquone (ATQ) and c.
proguanil (PG) against P. falciparum, strain K1. Synchronised trophozoite stage parasites were treated
with a two-fold dose series of the test compounds and analysed at 48 hours using the SYBR Green flow
cytometer method. Standard error bars are based on the standard error of the mean (SEM) for triplicate data.
doi:10.1371/journal.pone.0173303.g001
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levels (Fig 2C and 2D). Specifically, ∑FIC = 1.36, 1.38 and 1.53, whilst CI = 1.15, 1.32 and 1.53
at the ED50, ED75 and ED90 levels, respectively. Interactivity classification applied to ∑FIC
values are highly varied in the literature whilst CI criteria adhere to strict pre-defined classifi-
cation ranges and infer slight antagonism at ED50, moderate antagonism at ED75 and antago-
nism at ED90 (Table 1). Good correlations coefficients of the median-effect plot were reported
for dihydroartemisinin (r = 0.91), emetine (r = 0.93), and the combination (r = 0.89), inferring
good conformity to the mass-action law (Table 3).
Optimisation of atovaquone-proguanil dosing and treatment period
The atovaquone-proguanil combination was selected as known antimalarial synergists to vali-
date the CalcuSyn drug interactivity software for malaria. The compounds were combined
Fig 2. Comparison of dose-effect and FIC analysis for the dihydroartemisinin-emetine constant-ratio
combination. Parasites were treated with a dose series of chloroquine, emetine and the combination. Dose
ranges for individual and combined drugs were completed in triplicate. Dose-effect analysis was completed in
accordance with Chou Talalay method using CalcuSyn. An isobologram was also prepared manually from the
same, constant-ratio (ED50: ED50), dose-response data based on∑FIC analysis. The dose-effect curve (a),
the median-effect plot (b) and the isobologram (c) from the CalcuSyn output are shown alongside the FIC
isobologram (d) For the ED50 ED75 and ED90 levels of inhibition.
doi:10.1371/journal.pone.0173303.g002
Table 3. CalcuSyn output for the dihydroartemisin-emetine combination.
Drug ED50 ED75 ED90 Dm m r
FICDHA 0.772 0.710 0.736 N/A N/A N/A
FICDHA 0.592 0.675 0.796 N/A N/A N/A
∑ FICDHA+Eme 1.363 1.384 1.534 N/A N/A N/A
DHA N/A N/A N/A 2.817 1.199 0.911
Eme N/A N/A N/A 58.774 1.540 0.925
CIDHA+Eme 1.147 1.316 1.526 2.184 1.116 0.887
The combinatory index values (CI) potency at ED50 (Dm), shape of the curve (m = 1, > 1, and < 1 signify hyperbolic, sigmoidal, and flat sigmoidal
respectively) and the linear correlation coefficient (r) presented in the table accompany the CalcuSyn output data presented in Fig 2 for the
dihydroartemisinin-emetine combination against P. falciparum, strain K1 for 48 hours treatment at a constant ratio of 1:10.
doi:10.1371/journal.pone.0173303.t003
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under a constant-ratio in accordance with previously determined ED50 values (ED50:ED50).
Initially, the combination failed to show a marked increase in growth suppression when com-
pared with the drug-alone counterparts and the atovaquone dose-series did not achieve
expected level of inhibition (Fig 3A). Despite a subsequent increase in dose-series, and up to
80% inhibition with atovaquone, a similar dose-response pattern emerged, and no evidence of
synergy was apparent (Fig 3B). In both cases, inhibition for the combination was comparable
to that of proguanil alone (Fig 3A and 3B). Finally, the extension of the treatment period from
48 hours to 72 hours did reveal a slight increase growth suppression in the combination, had
the effect not been masked by the higher potency of atovaquone (Fig 3C). Accordingly, the
reduction of the atovaquone dose in the subsequent experiment and increase to 72 hour incu-
bation provided data whose analysis revealed the expected ‘very strong synergism’ interaction
using CalcuSyn at the ED50 and ED75 levels of inhibition and ‘strong synergism’ at the ED90
level of inhibition (Fig 4 and Table 4).
Further evaluation of SYBR Green-based P. falciparum viability using
the atovaquone-proguanil combination
In order to determine if parasite viability was misinterpreted by the SG-FCM method, parasite
recovery and regrowth was monitored after exposure to constant ratio and non-constant ratio
combinations of ATQ and PG. After 72 hrs of treatment the drugs were removed, parasites
were subjected to a limiting serial dilution and allowed to recover for a further 17 days. The
data showed that the combinations were more lethal than the drug alone treatments (Fig 5A–
5D). After 72 hours of treatment the SG-FCM assay detected some remaining live parasites in
all single and combined doses (Fig 5B and 5C), however, after 20 days, parasite growth was
detected in the drug alone treatments but not in any of the constant ratio combinations (Fig
5D) There appears to be growth in some of the non-constant ratio dose treatments after 20
days. However in all cases growth was detected in only 1 out of 3 triplicates and the parasitae-
mia was only marginally above the background threshold of 0.2% parasitaemia (0.3, 0.2, 0.33
and 0.23 for ED25 ATQ + ED50 PG, ED50 ATQ + ED25 PG, EDC75 ATQ + ED25 PG and ED75
ATQ + ED50 PG respectively). The presence/ absence scoring system (viable parasites = X
n-1)
therefore skewed the data in these cases. Indeed control and drug alone treatments achieved
parasitaemias of up to ~ 20% at the same dilution. A dose-response pattern could be observed
in the drug alone treatments after 20 days of incubation confirming the reliability of the data.
Although there appears to be the same level of regrowth at the ED25 and ED50 levels of inhibi-
tion for proguanil (growth present in the first two limiting serial dilutions for all concentrations)
the parasitaemia showed a dose-response pattern. First dilution parasitaemias were 3.4% (SE ±
0.15) and 2.2% (SE ± 0.25) and second dilution parasitaemias were 0.83% (SE ± 0.06) and 0.60%
(SE ± 0.03) for ED25 and ED50 doses respectively (control first dilution: 4.4% (SE ± 0.7) and sec-
ond dilution: 3.7% (SE ± 0.16)). Although after 72 hours the highest dose of proguanil achieved
nearly the same level of inhibition as the combinations, singly treated parasites were able to
recover (after 17 days) whilst those subjected to the combinations were not.
Defining the interactivity of emetine in combination with existing
antimalarials
Three current antimalarial drugs, dihydroartemisinin (DHA), chloroquine (CQ) and atova-
quone (ATQ) were investigated for their interaction with emetine dihydrochloride hydrate
(Eme) using the optimised 72 hour treatment regimen. The constant-ratio for each combina-
tion was selected based on the respective predetermined ED50 values for each compound. The
data for all of the combinations showed good conformity to the mass action law (r = 0.85–
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Fig 3. Optimisation of the atovaquone-proguanil treatment regime. (a) Trophozoite stage parasites
(strain K1) were treated with a 2-fold dose series of atovaquone (ATQ), proguanil (PG) or a constant-ratio
combination of both drugs (ATQ+PG) for 48 hours. The mid-point was equated to the previously determined
ED50 value for each drug. (b) Was a replica of (a) but with an increased atovaquone dose series. (c) Ring
stage parasites were treated for 72 hours with a 3-point constant-ratio dose series of atovaquone and
proguanil either alone or in combination. SG-FCM method was used to analyse parasite growth. The
parasitaemia of drug treated samples was determined relative to untreated controls (100% parasitaemia).
Triplicate samples were used to derive error bars based on standard error of the mean (SEM).
doi:10.1371/journal.pone.0173303.g003
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0.97). After 72 hours of incubation, the DHA-Eme interaction was classified as antagonistic
(1:10 ratio) at all inhibitory levels analysed (Fig 6A and 6B, Table 5). The interaction between
chloroquine and emetine (4.6:1 ratio) at ED50, ED75 and ED90 levels inhibition was classified
as antagonism, antagonism and mild antagonism respectively (Fig 6C and 6D, Table 5). For
the atovaquone-emetine (ratio 1:46) combination the ED50 level of inhibition was classified as
synergism, the ED75 moderate synergism and ED90 moderate antagonism (Fig 6E and 6F,
Table 5).
Discussion
Use of the Chou-Talalay method for in vitro drug interactivity analysis
against malaria
Antimalarial interactivity analysis requires standardisation to overcome the contradictory clas-
sifications reported in the literature and the commonality of in vitro-in vivo disconnect. The
ease-of-use of a constant-ratio treatment regime and automated CalcuSyn analysis, could serve
as a standardised, objective starting point to analyse potential antimalarial combinations.
Indeed, other areas of parasitology have adopted CalcuSyn as an alternative to manual
Fig 4. Constant-ratio combination of atovaquone and proguanil. The dose-response curves for
atovaquone (ATQ), proguanil (PG) and the constant-ratio combination of the two drugs (a). Ring stage
parasites were treated for 72 hours and analysed using the SG-FCM method. Controls consisted of
uninfected blood, untreated controls and the highest dose of the acetonitrile: water (60:40) solvent for
proguanil. Triplicate data were normalised according to the controls. Error bars reflect the standard error of
the mean (SEM). The isobologram inset (b) shows the interactivity classifications for the constant-ratio
combination of atovaquone and proguanil at the ED50, ED75 and ED90 effect levels.
doi:10.1371/journal.pone.0173303.g004
Table 4. CalcuSyn output for the combination between atovaquone and proguanil.
Drug CI Values at
ED50 ED75 ED90 Dm m r
ATQ N/A N/A N/A 0.293 0.549 0.879
PG N/A N/A N/A 10960 1.408 0.962
ATQ+PG (1:7455) <0.001 0.004 0.295 2.2x10-5 0.198 0.825
The combinatory index values (CI) are shown for the ATQ + PG constant ratio combination (1:7455) and the ED50, ED75 and ED90 levels of inhibition. The
Dm, m and r values are also shown for all sets of data. Dm indicates potency and depicts the median-effect dose at the ED50 level of inhibition. The m value
refers to the kinetic order and shape of the curve m = 1, > 1, and < 1 indicates hyperbolic, sigmoidal, and negative sigmoidal shape, respectively. The r value
is the linear correlation coefficient for the median-effect plot and indicates conformity to the mass action law.
doi:10.1371/journal.pone.0173303.t004
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isobologram preparation for both fixed-ratio and checkerboard data [27–30]. For malaria, the
current study validated the use of CalcuSyn via comparison with Sum FIC data for the
DHA-Eme interaction and identification of a synergistic interaction for the known antimalar-
ial synergists, atovaquone and proguanil consistent with data reported elsewhere and in the
field [5, 7, 20]. Importantly, the work highlighted that many factors, such as treatment time-
course, viability assay and drug mode-of-action can confound interactivity classifications.
Indeed, initially there was no evidence of an interaction between atovaquone and proguanil
after 48 hours of treatment using the SYBR-Green-based flow cytometer assay. Solubility issues
of atovaquone, similarly reported by Canfield and colleagues (1995)[5], were first considered.
However, further work revealed that a 72 hour time-course was required for the identification
of synergy. This was not surprising, as atovaquone is known to be one of the slowest acting
antimalarials available [25], but contradicts the findings of Fivelman et al., (2004)[7], who
showed the atovaquone-proguanil combination to be synergistic within a 48 hour treatment
period using the hypoxanthine incorporation method. The problem may therefore be related
to the impact of drug-kill profile on the viability determinant. Wein et al., (2010)[31] suggest
that while the hypoxanthine incorporation method can be used at 48 hrs, the SYBR green-
based methods require a 72 hour exposure period to provide accurate data, as the read-out can
be differentially affected by drug mode-of-action, particularly cytocidal or cytostatic activities
of drugs [31, 32].This notion is supported by the observations that no drug dose used in the
study achieved 100% inhibition and different drugs plateau at different levels of inhibition,
with the combination probably mirroring the most DNA degrading of the two compounds.
Fig 5. Non-constant and constant-ratio data for the atovaquone-proguanil combination. Ring stage parasites were
treated for 72 hours with constant and non-constant ratio combinations of atovaquone and proguanil. Parasitaemia was
determined using the SG-FCM method (a and c). After 72 hours of treatment, drug pressure was removed; parasites were
subjected to 8 10-fold limiting serial dilutions and incubated for a further 17 days. Spent media was replaced with fresh media
and erythrocytes on day 7. On day 20, the presence or absence of growth in each well was determined using SC-FCM and
used to back calculate parasite viability after the 17 day recovery period (b and d). Triplicate data was used to construct error
bars that represented the standard error of the mean (SEM).
doi:10.1371/journal.pone.0173303.g005
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For this reason the ATQ PG combination was used to further understand the relationship
between SYBR Green viability and cytocidal versus cytostatic effects of drugs at higher levels
of inhibition. Following 72 hours of exposure with ATQ and PG alone and combination
Fig 6. The constant ratio combinations of dihydroartemisinin-emetine (a,b), chloroquine-emetine (c,
d) and atovaquone-emetine (e,f) using CalcuSyn. Parasite viability was analysed after 72 hours using
the SG-FCM method. A basic dose-response curve is shown as well as the isobolograms to indicate the
nature of the interaction for each constant-ratio (based on a 2-fold dose series where respective drug
ED50: ED50 doses serveed as the midpoint) combination at the ED50 ED75 and ED90 effect levels (Marker
below the line = synergistic, on the line = additive and above the line antagonistic). The degree of the
classification is indicated by the distance of the marker from the respective (colour coded) line.
doi:10.1371/journal.pone.0173303.g006
Table 5. Combinatory classification for emetine with existing antimalarials using the CalcuSyn analy-
sis method.
Drug CI Values at
ED50 ED75 ED90 r
DHA+Eme (1:10) 1.803 1.805 1.808 0.899
CQ+Eme (4.6:1) 1.469 1.489 1.517 0.877
ATQ+Eme (1:46) 0.516 0.834 1.403 0.912
The combinatory index values are shown for the combination at the ED50, ED75 and ED90 levels of inhibition.
The r value for each combination is also reported to indicate the correlation coefficient of the data to the
mass action law.
doi:10.1371/journal.pone.0173303.t005
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treatments an extended regrowth/recovery assay was conducted, in the absence of drug pres-
sure. The assumption was that if the failure to exceed 90% inhibition was indeed due to back-
ground effects recovery would be consistent across all conditions with similar levels of inhibition
at 72 hours. Interestingly, despite showing some remaining live parasites after 72 hours of treat-
ment, comparable to that of some single drug treatments, parasites treated with any of the con-
stant or non-constant ratio combinations did not recover to the same extent as their drug alone
counterparts. The regrowth/recovery assay therefore revealed that the SYBR Green based flow
cytometer assay misinterpreted parasite viability. At the highest levels of inhibition such errors
are likely to influence the interactivity definition at arguably the most important levels of inhibi-
tion in terms of parasite killing[8]. It is unlikely that such problems are unique to the SYBR
green assay, particularly as most drug-susceptibility assays, based on metabolic activity are sug-
gested to offer poor surrogates for parasite viability and have also been reported to be differen-
tially affected by the mechanistic actions of drugs [25, 31]. However, since most antimalarial
combinatory analyses are conducted at the ED50 level of inhibition it is likely that such issues
have been commonly overlooked by other screens. With such variability in experimental set up
between screens, it is perhaps predictable that interactivity classifications reported in the litera-
ture are often inconsistent and translate poorly in the in vivo setting. Drug killing-profile data
based on limiting serial dilutions, has been shown to generate in vitro pharmacokinetic (PK) and
pharmacodynamic (PD) data that correlates well with in vivo PK/PD data [25]. Better in vitro to
in vivo translation may therefore be achieved for drug combination analysis if more detailed sec-
ond-phase in vitro drug combinatory analyses determined the drug interactivity outcome after
drug wash-out and regrowth/recovery period, when parasite viability is definitive [18, 25, 33,
34].
A separate issue in terms of the in vitro to in vivo disconnect, is that in vivo combination
ratios are affected by pharmacokinetic and pharmacodynamic aspects of the individual com-
pounds. This makes the selection of an appropriate ratio at the in vitro level difficult, particu-
larly, as in most cases, different ratios present different interaction classifications [8]. The
value of identifying desirable interactions in vitro also becomes redundant if such ratios cannot
be achieved in the in vivo situation. The CalcuSyn constant ratio option therefore serves as a
good starting point, offering a user-friendly, objective route to achieve preliminary drug inter-
action data by employing a single-ratio, across a dose series, based on pre-defined ED50 values
[6, 28, 30]. Second-phase combinatory analysis should therefore also include the evaluation of
a wider range of pharmacokinetically appropriate drug ratios.
Defining the interactivity of emetine in combination with existing
antimalarials
The preliminary data predict that the DHA-Eme and CQ-Eme combinations would not be
efficacious in vivo. Interestingly like emetine, chloroquine has also been used previously to
treat amoebiasis [13]. In this protozoan parasite, the drugs were found to act on different
parasite targets. Chloroquine was shown to inhibit DNA synthesis in the vegetative forms of
the parasite, while emetine killed the trophozoite stage by inhibiting protein synthesis [13].
Indeed, emetine has been commonly reported as a protein synthesis inhibitor in other organ-
isms including bacteria [11, 35]. Recent work by Wong and colleagues (2014) has solved the
structure of the 80s P. falciparum cytoplasmic ribosome, with emetine bound to the E-site on
the 40s subunit, confirming that such a target extends to the malaria parasite [36].
Interestingly, the combination between atovaquone and emetine was shown to be synergis-
tic at ED50 and ED75 levels on inhibition but antagonistic at ED90 level. In other studies spo-
radic cases of antagonism in combinations that are otherwise synergistic have been reported
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[19]. However due to the previous findings, at high levels of inhibition where differences in
inhibition are less pronounced the misinterpretation of parasite viability could be responsible
for the contrary classifications presented. We have recently shown that similar to atovaquone,
emetine has a slow killing profile against the malaria parasite (unpublished data). Interestingly,
compounds with similar killing profiles have been shown to have similar parasite targets [25].
Atovaquone is known to act via the cytochrome bc1 complex in the malaria parasite mito-
chondria [37]. Coincidently, in the parasite, protein synthesis is known to occur at two other
centres in addition to the cytosol: namely: the apicoplast and the mitochondria [36]. Both
organelles are thought to have originated from separate endosymbiotic events of bacteria.
Taken together, the relatively slow killing profile of emetine, mimicking that of atovaquone,
the bacterial nature of the mitochondria and its involvement in protein synthesis infers that
the preferential target of emetine may be the mitochondrial ribosome. The hypothesis would
favour the synergistic activity reported here between the two drugs, possibly through activity
on different targets in the mitochondria [15]. However such theories would require a more
detailed inquiry and cannot be deduced from the data presented here alone. Nonetheless, pre-
liminary evidence of a potentially pharmacokinetic-matched, synergetic combination presents
an exciting opportunity for antimalarial development, providing dose-dependent toxicity can
be overcome. Indeed, recent findings that atovaquone resistant parasites were not transmissi-
ble suggest the mitochondria may be a good drug target in terms of transmission intervention
[38]. Further investigation will be needed to establish whether the combination will be effica-
cious in vivo.
Despite being identified as a recurring hit in high throughput screens [14, 39, 40], the value
of emetine for malaria treatment has been largely overlooked due to concerns about its toxicity
profile. The identification of a synergistic interaction between emetine and atovaquone further
validates emetine dihydrochloride hydrate as a valuable antimalarial candidate and presents a
potential route to minimise dose-related toxicity previously reported for the drug. Our further
work will be focussed on evaluating other combinatorial options for the compound and
attempting the synthesis of less toxic derivatives of the molecule in a bid to reduce undesirable,
non-target effects. The recent and timely resolution of the cryo-EM structure of emetine in
complex with its target on the E-site of the P. falciparum ribosomal small subunit, provides a
useful tool to enable further modification of the molecule [36]. In the current backdrop of an
impending void in the antimalarial drug market due to evolving artemisinin resistance, it is
vital that powerful and affordable candidates like emetine are investigated further.
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